The current STATe of biomarkers to predict the response to anti-angiogenic therapies

Cancer Biol Ther. 2008 Dec;7(12):2004-6. doi: 10.4161/cbt.7.12.7191.
No abstract available

Publication types

  • Comment

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use
  • Bevacizumab
  • Cell Division / drug effects
  • Humans
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Neovascularization, Pathologic / prevention & control*
  • STAT3 Transcription Factor / drug effects
  • STAT3 Transcription Factor / physiology
  • Vascular Endothelial Growth Factor Receptor-2 / drug effects
  • Vascular Endothelial Growth Factor Receptor-2 / physiology*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Bevacizumab
  • Vascular Endothelial Growth Factor Receptor-2